Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | CDA | P32320 | 1/20 | 0.63 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.58 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.58 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.58 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | MTOR | P42345 | 2/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.56 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.56 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.56 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.53 |
| ▸ | GMNN | O75496 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.49 |
| ▸ | THPO | P40225 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9293543 | 1.00 | MAPT (0.63) | MAPTCDASLC28A1SLC28A2SLC29A1 | |
| SCHEMBL7028251 | 1.00 | MAPT (0.63) | MAPTCDASLC28A1SLC28A2SLC29A1 | |
| SCHEMBL26554475 | 0.87 | CDA (0.49) | MAPTCDASLC28A1SLC28A2SLC29A1 | |
| SCHEMBL26554460 | 0.87 | MAPT (0.48) | MAPTCDASLC28A1SLC28A2SLC29A1 | |
| SCHEMBL6672239 | 0.79 | MAPT (0.60) | MAPTCDASLC28A1SLC28A2SLC29A1 | |
| SCHEMBL9293560 | 0.79 | SLC28A1 (0.59) | MAPTCDASLC28A1SLC28A2SLC29A1 | |
| SCHEMBL4293684 | 0.79 | SLC28A1 (0.59) | MAPTCDASLC28A1SLC28A2SLC29A1 | |
| SCHEMBL13657982 | 0.79 | SLC28A1 (0.59) | MAPTCDASLC28A1SLC28A2SLC29A1 | |
| SCHEMBL352974 | 0.79 | SLC28A1 (0.59) | MAPTCDASLC28A1SLC28A2SLC29A1 | |
| SCHEMBL12594002 | 0.79 | SLC28A1 (0.59) | MAPTCDASLC28A1SLC28A2SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024168196-A1 | SYSTEMS AND METHODS FOR ENZYMATIC SYNTHESIS OF POLYNUCLEOTIDES CONTAINING NON-STANDARD NUCLEOTIDE BASEPAIRS | UNIVERSITY OF WASHINGTON (US) | 2024-08-15 | — | — | WO | disclosed |
| US-20240200071-A1 | NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF A TARGET GENE COMPRISING PHOSPHORODITHIOATE LINKAGES | SILENCE THERAPEUTICS GMBH (DE) | 2024-06-20 | — | — | US | disclosed |
| US-11873489-B2 | Nucleic acids for inhibiting expression of a target gene comprising phosphorodithioate linkages | SILENCE THERAPEUTICS GMBH (DE) | 2024-01-16 | — | — | US | disclosed |
| US-20210155926-A1 | siRNAs WITH AT LEAST TWO LIGANDS AT DIFFERENT ENDS | SILENCE THERAPEUTICS GMBH (DE) | 2021-05-27 | — | — | US | disclosed |
| EP-3775209-A1 | SIRNAS WITH AT LEAST TWO LIGANDS AT DIFFERENT ENDS | Silence Therapeutics GmbH (DE) | 2021-02-17 | — | — | EP | disclosed |
| US-20200392495-A1 | NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF A TARGET GENE COMPRISING PHOSPHORODITHIOATE LINKAGES | SILENCE THERAPEUTICS GMBH (DE) | 2020-12-17 | — | — | US | disclosed |
| EP-3710585-A1 | NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF A TARGET GENE COMPRISING PHOSPHORODITHIOATE LINKAGES | Silence Therapeutics GmbH (DE) | 2020-09-23 | — | — | EP | disclosed |
| WO-2019193189-A1 | siRNAs WITH AT LEAST TWO LIGANDS AT DIFFERENT ENDS | SILENCE THERAPEUTICS GMBH (DE) | 2019-10-10 | — | — | WO | disclosed |
| EP-3549610-A1 | NUCLEIC ACID CONJUGATES | Silence Therapeutics GmbH (DE) | 2019-10-09 | — | — | EP | disclosed |
| WO-2018185252-A1 | NUCLEIC ACID CONJUGATES | SILENCE THERAPEUTICS GMBH (DE) | 2018-10-11 | — | — | WO | disclosed |
| WO-2018185253-A1 | LIGAND MODIFIED DOUBLE-STRANDED NUCLEIC ACIDS | SILENCE THERAPEUTICS GMBH (DE) | 2018-10-11 | — | — | WO | disclosed |
| EP-3052479-A2 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2016-08-10 | — | — | EP | disclosed |
| WO-2015051173-A2 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC (US) | 2015-04-09 | — | — | WO | disclosed |
| US-20030170644-A1 | Method for screening nucleic acid catalysts | RIBOZYME PHARMACEUTICALS, INC. | 2003-09-11 | — | — | US | disclosed |
| US-20030144489-A1 | Method for screening nucleic acid catalysts | RIBOZYME PHARMACEUTICALS, INC. | 2003-07-31 | — | — | US | disclosed |
| EP-1321521-A1 | Ribozymes directed against flt-1 | RIBOZYME PHARMACEUTICALS, INC. (US) | 2003-06-25 | — | — | EP | disclosed |
| US-6548657-B1 | Synthesis of ribozyme libraries and gene sequences | RIBOZYME PHARMACEUTICALS, INC. | 2003-04-15 | — | — | US | disclosed |
| US-6280936-B1 | USEFUL FOR CLEAVAGE OF RIBONUCLEIC ACID (RNA) AND DEOXYRIBONUCLEIC ACID | RIBOZYME PHARMACEUTICALS, INC. | 2001-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030170644-A1 | Method for screening nucleic acid catalysts | RNGTT, POLRMT, RNASE1 | MAPT 4572/4885CDA 35/4885SLC28A1 868/4885 |
| US-20210155926-A1 | siRNAs WITH AT LEAST TWO LIGANDS AT DIFFERENT ENDS | NSUN3, SNRPE, RNASE1 | MAPT 4666/4885CDA 457/4885SLC28A1 1860/4885 |
| US-20030144489-A1 | Method for screening nucleic acid catalysts | POLM, POLRMT, RNGTT | MAPT 4364/4885CDA 46/4885SLC28A1 1028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.